专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090264384A1 INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF 审中-公开
标题翻译：吲哚，苯并咪唑和苯并咪唑硼酸化合物，其模拟物及其使用方法
公开(公告)号：US20090264384A1
公开(公告)日：2009-10-22
申请号：US12268237
申请日：2008-11-10
申请人： John R. Didsbury , Tatyana Dyakonov , Simon N. Haydar , Michael L. Jones , Francine F. Li , Christopher J. Markworth , Jessy Matthew , Frank J. Schoenen , Jan J. Scicinski , David Middlemiss , James F. Burns , Leonard A. Cabana , Glenn C. Collupy , David N. Vanvliet
发明人： John R. Didsbury , Tatyana Dyakonov , Simon N. Haydar , Michael L. Jones , Francine F. Li , Christopher J. Markworth , Jessy Matthew , Frank J. Schoenen , Jan J. Scicinski , David Middlemiss , James F. Burns , Leonard A. Cabana , Glenn C. Collupy , David N. Vanvliet
IPC分类号： A61K31/69 , A61P1/00 , A61P19/02 , A61P17/06 , A61P11/06 , A61P11/00 , A61P17/00 , A61P37/08
CPC分类号： A61K31/69 , Y02A50/411
摘要： Benzimidazole, indole and benzolactam boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.
摘要翻译：还描述了苯并咪唑，吲哚和苯并内酰胺硼酸化合物，其类似物和药物制剂，以及其用于抑制有需要的受试者中的炎性细胞因子如肿瘤坏死因子α（TNF-α）的方法。

2. 发明申请

US20090005344A1 Compounds and Methods of Use Thereof 审中-公开
标题翻译：化合物及其使用方法
公开(公告)号：US20090005344A1
公开(公告)日：2009-01-01
申请号：US11718277
申请日：2005-10-27
申请人： James F. Burns , Leonardo A. Cabana , Glenn C. Collupy , John R. Didsbury , Tatyana A. Dyakonov , Simon N. Haydar , Michael L. Jones , Francine F. Li , Christopher J. Markworth , Jessymol Mathew , Frank J. Schoenen , David S. Van Vliet , David Middlemiss
发明人： James F. Burns , Leonardo A. Cabana , Glenn C. Collupy , John R. Didsbury , Tatyana A. Dyakonov , Simon N. Haydar , Michael L. Jones , Francine F. Li , Christopher J. Markworth , Jessymol Mathew , Frank J. Schoenen , David S. Van Vliet , David Middlemiss
IPC分类号： A61K31/4184 , A61K31/381 , A61P43/00 , A61P29/00 , A61P19/02 , A61P17/06 , A61P19/08 , A61P11/06
CPC分类号： C07F5/025 , C07D235/18 , C07D417/04
摘要： Imidazole and benzimidazole boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.
摘要翻译：描述了咪唑和苯并咪唑硼酸化合物，其类似物和药物制剂，以及其用于抑制有需要的受试者中的炎性细胞因子如肿瘤坏死因子α（TNF-α）的方法。

3. 发明申请

US20080319044A1 Compounds and Methods of Use Thereof 审中-公开
标题翻译：化合物及其使用方法
公开(公告)号：US20080319044A1
公开(公告)日：2008-12-25
申请号：US11718286
申请日：2005-10-27
申请人： John R. Didsbury , Tatyana A. Dyakonov , Simon N. Haydar , Michael L. Jones , Francine F. Li , Christopher J. Markworth , Jessymol Mathew , Frank J. Schoenen , Jan J. Scicinski , David Middlemiss
发明人： John R. Didsbury , Tatyana A. Dyakonov , Simon N. Haydar , Michael L. Jones , Francine F. Li , Christopher J. Markworth , Jessymol Mathew , Frank J. Schoenen , Jan J. Scicinski , David Middlemiss
IPC分类号： A61K31/404 , C07D209/04 , A61P1/00 , A61P19/02 , A61P17/06 , A61P25/28 , A61P9/00 , A61P3/10 , A61P35/00 , A61P9/12 , A61P15/10
CPC分类号： C07D491/04 , C07D209/08 , C07F5/025
摘要： Indole boronic acid compounds, and analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.
摘要翻译：描述了吲哚硼酸化合物及其类似物和药物制剂，以及其用于抑制有需要的受试者中的炎性细胞因子如肿瘤坏死因子α（TNF-α）的方法。

4. 发明申请

US20080269204A1 Compounds and Methods of Use Thereof 审中-公开
标题翻译：化合物及其使用方法
公开(公告)号：US20080269204A1
公开(公告)日：2008-10-30
申请号：US11718284
申请日：2005-10-27
申请人： Tatyana Dyakonov , Michael L. Jones , Christopher J. Markworth , Jessymol Mathew , Frank J. Schoenen , David S. Van Vliet , David Middlemiss
发明人： Tatyana Dyakonov , Michael L. Jones , Christopher J. Markworth , Jessymol Mathew , Frank J. Schoenen , David S. Van Vliet , David Middlemiss
IPC分类号： C07D279/16 , A61K31/5415 , C07D265/36 , A61P1/00 , A61P17/06 , A61P11/00 , A61P3/10 , A61P9/12 , A61P15/10 , A61P35/00 , A61P25/28 , A61P11/06 , A61P19/02 , A61P29/00 , A61K31/536
CPC分类号： C07F5/025
摘要： Benzolactam boronic acid compounds and pharmaceutical formulations are described along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.
摘要翻译：本文描述了苯甲酰硼酸化合物和药物制剂及其用于抑制有需要的受试者中的炎性细胞因子如肿瘤坏死因子α（TNF-α）的方法。

5. 发明授权

US5326760A Aminobutanoic acid compounds having metalloprotease inhibiting properties 失效
标题翻译：具有金属蛋白酶抑制性质的氨基丁酸化合物
公开(公告)号：US5326760A
公开(公告)日：1994-07-05
申请号：US31439
申请日：1993-03-15
申请人： Andrew B. McElroy , Peter J. Brown , David H. Drewry , James M. Salovich , Frank J. Schoenen
发明人： Andrew B. McElroy , Peter J. Brown , David H. Drewry , James M. Salovich , Frank J. Schoenen
IPC分类号： C07C237/06 , C07D209/48 , C07D209/66 , C07D213/40 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D487/04 , C07F7/18 , A61K31/395 , A61K31/40
CPC分类号： C07D209/48 , C07C237/06 , C07D209/66 , C07D213/40 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D487/04 , C07F7/1852 , C07F7/1856
摘要： Aminobutanoic acids of the following formula (I): ##STR1## where R.sup.1 -R.sup.5 are a variety of substituents, novel intermediates, a pharmaceutical composition for treating inflammatory diseases, demyelinating diseases, and tumor metastasis, methods for such treatment and processes for preparing compounds of formula (I).
摘要翻译：下式（I）的氨基丁酸：其中R1-R5是多种取代基，新型中间体，用于治疗炎性疾病，脱髓鞘疾病和肿瘤转移的药物组合物，其用于治疗和治疗的方法用于制备式（I）的化合物。

6. 发明授权

US09463495B2 Laboratory fume hood system having recessed heat exchanger system 有权
标题翻译：具有凹陷式热交换器系统的实验室通风柜系统
公开(公告)号：US09463495B2
公开(公告)日：2016-10-11
申请号：US13966496
申请日：2013-08-14
申请人： George S. Wilson , William Scott Jeffress , Frank J. Schoenen
发明人： George S. Wilson , William Scott Jeffress , Frank J. Schoenen
IPC分类号： B08B15/02 , F28D15/00 , F28D21/00 , B23P19/00 , B01L1/00 , B01L7/00
CPC分类号： B08B15/023 , B01L1/50 , B01L7/00 , B01L2300/185 , B23P19/00 , F28D15/00 , F28D2021/0019 , Y10T29/49826
摘要： A laboratory fume hood system for cooling at least one laboratory device located in an interior work area comprises a heat exchanger system having a heat exchanger in thermal communication with a primary fluid loop containing chilled fluid and a secondary fluid loop containing a cooling fluid which is in thermal communication the laboratory device. The primary fluid loop is located behind the fume hood wall and not in the interior work area.
摘要翻译：用于冷却位于内部工作区域中的至少一个实验室设备的实验室通风柜系统包括热交换器系统，其具有与包含冷冻流体的主要流体回路热连通的热交换器和包含冷却流体的次级流体回路热通讯实验室设备。主流体回路位于通风橱壁后面，而不在室内工作区域。

7. 发明授权

US09289760B2 Apparatus for providing coolant fluid 有权
标题翻译：用于提供冷却剂流体的装置
公开(公告)号：US09289760B2
公开(公告)日：2016-03-22
申请号：US12393362
申请日：2009-02-26
申请人： Gerald G. Williams , Andrew D. Hager , George S. Wilson , William Scott Jeffress , Frank J. Schoenen
发明人： Gerald G. Williams , Andrew D. Hager , George S. Wilson , William Scott Jeffress , Frank J. Schoenen
IPC分类号： B01L1/00
CPC分类号： B01L1/50 , B01L2300/185
摘要： An apparatus for providing coolant fluid to a device, the apparatus includes a heat exchanger having a hot side and a cold side. The cold side is in fluid communication with a chilled fluid supply and adapted to receive a first fluid from the chilled fluid supply in a first inlet and return the first fluid from the cold side to the chilled fluid supply. The cold side and the chilled fluid supply form a first fluid circuit. The apparatus further includes a second fluid circuit in fluid communication with the hot side, means for introducing a second fluid within the second fluid circuit and integral thereto, a pump integral to the second fluid circuit and adapted to transmit a second fluid within the second fluid circuit and means for controlling a rate of flow of the second fluid within the second fluid circuit. The device is within the second fluid circuit and the means for controlling the rate of flow operates in the absence of internal recirculation.
摘要翻译：一种用于向装置提供冷却剂流体的装置，该装置包括具有热侧和冷侧的热交换器。冷侧与冷却液供应流体连通并且适于在第一入口中从冷冻流体供应源接收第一流体并将第一流体从冷侧返回到冷却液供应。冷侧和冷却液供应形成第一流体回路。该装置还包括与热侧流体连通的第二流体回路，用于在第二流体回路内引入第二流体并与其成一体的装置，与第二流体回路成一体的泵，适于在第二流体内传输第二流体电路和用于控制第二流体回路内的第二流体的流量的装置。该装置在第二流体回路内，用于控制流量的装置在没有内部再循环的情况下运行。

8. 发明申请

US20090170842A1 BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE 审中-公开
标题翻译：基于BRCA1的乳腺癌或卵巢癌预防剂及其使用方法
公开(公告)号：US20090170842A1
公开(公告)日：2009-07-02
申请号：US12270252
申请日：2008-11-13
申请人： Roy A. Jensen , Lisa M. Harlan-Williams , Frank J. Schoenen , Jeffrey Aube , Gerald H. Lushington
发明人： Roy A. Jensen , Lisa M. Harlan-Williams , Frank J. Schoenen , Jeffrey Aube , Gerald H. Lushington
IPC分类号： A61K31/5375 , A61K31/423 , A61K31/426 , A61K31/4245 , A61K31/505 , A61K31/381 , A61K31/164 , A61K31/41 , A61K31/4709 , A61K31/343 , A61K31/415 , A61K31/34 , A61K31/13 , A61K31/44 , A61K31/4035 , C07D235/04 , A61K31/4184 , C12N5/00 , A61P35/00
CPC分类号： A61K31/403 , A61K31/13 , A61K31/164 , A61K31/34 , A61K31/343 , A61K31/381 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/44 , A61K31/4709 , A61K31/505 , A61K31/5375
摘要： A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.
摘要翻译：用于治疗，抑制和/或预防乳房和/或卵巢癌的药物组合物可以包括：具有化合物1-38之一结构的分子，其药学上可接受的盐或其类似物和药学上可接受的载体含有该化合物。药学上可接受的载体可以配置为口服，全身，透皮，鼻内，栓剂，胃肠外，肌内，静脉内或皮下给药。化合物可以以治疗有效量存在于组合物中，用于治疗，抑制和/或预防乳腺和/或卵巢癌。此外，化合物可以以治疗有效量存在，以增强BRCA1的产生。

9. 发明授权

US08865708B2 Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase 有权
标题翻译：抑制过渡性内质网ATP酶的方法和组合物
公开(公告)号：US08865708B2
公开(公告)日：2014-10-21
申请号：US13103003
申请日：2011-05-06
申请人： Raymond J. Deshaies , Tsui-Fen Chou , Frank J. Schoenen , Kelin Li , Kevin J. Frankowski , Jeffrey Aube , Samuel W. Gerritz , Han-Jie Zhou
发明人： Raymond J. Deshaies , Tsui-Fen Chou , Frank J. Schoenen , Kelin Li , Kevin J. Frankowski , Jeffrey Aube , Samuel W. Gerritz , Han-Jie Zhou
IPC分类号： A61K31/54 , A61K31/535 , A61K31/538 , A61K31/517 , A61K31/4184 , C12Q1/42 , A61K31/53 , C12Q1/48
CPC分类号： A61K31/517 , A61K31/4184 , A61K31/53 , A61K31/538 , C12Q1/42 , C12Q1/485 , G01N2500/02
摘要： Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof.
摘要翻译：式I-XLIII的化合物被鉴定为p97 ATPase的直接抑制剂或p97依赖性泛素 - 蛋白酶体系统（UPS）底物的降解。公开了用于抑制p97 ATP酶和p97依赖性UPS底物的降解以及鉴定其抑制剂的方法和组合物。

10. 发明授权

US08362072B2 BRCA1-based breast or ovarian cancer treatment agents and methods of use 失效
标题翻译：基于BRCA1的乳腺癌或卵巢癌治疗剂及其使用方法
公开(公告)号：US08362072B2
公开(公告)日：2013-01-29
申请号：US13525831
申请日：2012-06-18
申请人： Roy A. Jensen , Lisa M. Harlan-Williams , Frank J. Schoenen , Jeffrey Aube , Gerald H. Lushington
发明人： Roy A. Jensen , Lisa M. Harlan-Williams , Frank J. Schoenen , Jeffrey Aube , Gerald H. Lushington
IPC分类号： A61K31/34
CPC分类号： A61K31/403 , A61K31/13 , A61K31/164 , A61K31/34 , A61K31/343 , A61K31/381 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/44 , A61K31/4709 , A61K31/505 , A61K31/5375
摘要： A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.
摘要翻译：用于治疗，抑制和/或预防乳房和/或卵巢癌的药物组合物可包括：具有化合物1-38之一结构的分子，其药学上可接受的盐或其类似物; 和含有该化合物的药学上可接受的载体。药学上可接受的载体可以配置为口服，全身，透皮，鼻内，栓剂，胃肠外，肌内，静脉内或皮下给药。化合物可以以治疗有效量存在于组合物中，用于治疗，抑制和/或预防乳腺和/或卵巢癌。此外，化合物可以以治疗有效量存在，以增强BRCA1的产生。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式